Roquefort Therapeutics (LON:ROQ) Shares Down 2.1% – Time to Sell?

Roquefort Therapeutics plc (LON:ROQ) shares traded down 2.1% during mid-day trading on Thursday . The company traded as low as GBX 3.50 ($0.04) and last traded at GBX 3.77 ($0.05). 1,022,574 shares traded hands during trading, a decline of 21% from the average session volume of 1,298,604 shares. The stock had previously closed at GBX 3.85 ($0.05).

Roquefort Therapeutics Stock Down 7.6 %

The business’s fifty day moving average price is GBX 4.30 and its 200 day moving average price is GBX 4.12. The firm has a market capitalization of £4.59 million, a price-to-earnings ratio of -355.60 and a beta of 0.05. The company has a current ratio of 0.79, a quick ratio of 3.07 and a debt-to-equity ratio of 12.37.

About Roquefort Therapeutics

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.